Fiber Fermentation Study

Effects Dietary Fiber From Grains or Fruits and Vegetables on the Intestinal Production of Short-chain Fatty Acids

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04570137

Enrollment

Registered

2020-09-30

Start date

2020-07-06

Completion date

2020-10-01

Last updated

2021-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal Health

Keywords

Gastroenterology, Gut microbiome, Gut barrier

Brief summary

The aim of the study is to better understand the interplay between the intake of dietary fiber and intestinal bacteria, their metabolic activity and the effect on the intestinal barrier. The effect of two different dietary fiber supplements is tested (arabinoxylan & ß-glucan versus inulin & fructooligosaccharides) in a randomized crossover intervention trial including healthy volunteers.

Interventions

DIETARY_SUPPLEMENTDietary fiber supplementation

1. 16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan) 2. 16g/day: mix of 50% inulin and 50% oligofructose from chicory

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Intervention model description

Two-armed crossover trial

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* 18 to 65 years * signed written informed consent * willingness not to change the dietary pattern in the course of the study

Exclusion criteria

* BMI below 18 or above 30 * acute or chronic gastrointestinal symptoms * neoplastic diseases * very strict diets, including raw foodists and frutarians * regular smoking (more than one box per day) * intake of antibiotics, immunosuppressants, or any intestinal therapeutics three months prior to study begin * supplementation of fibers three months prior to study begin * simultaneous participation in another clinical study * pregnancy / breastfeeding * relevant violations of the study protocol * intolerance to the fiber supplements (including wheat, oat, chicory) * occurrence of relevant diseases (individual decision by study physicians) * revocation of consent * placement in a clinic or similar facility based on an official or court order

Design outcomes

Primary

Measure	Time frame	Description
Short-chain fatty acids (SCFAs)	Will be measured in approx. 4 weeks after study completion.	SCFAs in native fecal samples

Secondary

Measure	Time frame	Description
Gut microbiome composition	Will be measured in approx. 6-8 weeks after study completion.	16S NGS sequencing
Gut barrier integrity	Will be measured in approx. 4 weeks after study completion.	Lipopolysaccharide-binding protein (plasma) and zonulin (feces)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026